Phospholipase C (PLC)

Phospholipase C is a family of membrane-associated enzymes that catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP₂) into two important second messengers: diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP₃). This reaction is central to eukaryotic signal transduction pathways regulating diverse physiological processes such as cell proliferation, differentiation, metabolism regulation via protein kinase cascades—including PKC—and modulation of intracellular calcium levels through IP₃-mediated release from endoplasmic reticulum stores. There are multiple mammalian isoforms classified into several families—β(PLCβ), γ(PLCγ), δ(PLCδ), ε(PLCε), ζ(PLCζ), η(PLCη)—each with distinct regulatory mechanisms and tissue distributions. Dysregulation or mutation within these pathways has been implicated in cancer progression/oncogenesis as well as inflammatory diseases and cardiovascular pathologies. Due to their essential role across many systems and complex regulation by G proteins/tyrosine kinases/calcium/phosphoinositides/protein-protein interactions, therapeutic targeting requires high specificity toward individual isoforms involved in pathological conditions while sparing normal physiological functions.

Other names

PLCPI-PLC (Phosphatidylinositol-specific phospholipase C)Phosphoinositide phospholipase CPhosphatidylinositol phospholipase C

Drugs or compounds that target phospholipase C typically act by inhibiting its enzymatic activity, thereby reducing the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which leads to decreased downstream signaling such as reduced intracellular calcium release and protein kinase C activation. Some agents may also modulate upstream activators or downstream effectors.